EligibleTrials

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

Recruiting · NCT05287126 · Interventional (participants receive a specific treatment) · Lead sponsor: Pfizer

View the official record on ClinicalTrials.gov →
Ulcerative Colitis

Interventions studied

Etrasimod

What this trial is about

The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to \< 18 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study enrollment).

Who can take part

Age range
12 Years to 17 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

45 locations listed across 8 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.